EANS-Adhoc: Marseille-Kliniken AG: Result improvement in business year 2011/2012
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- 01.10.2012 Hamburg, 01 October 2012 - Marseille-Kliniken AG (Prime Standard, ISIN DE0007783003, MKA) has achieved an increase in results in business year 2011/2012 (1 July - 30 June). Revenues increased to EUR 195.1 million. EBIT increased to EUR 10.9 million, earnings per share moved to EUR 0.45 (previous year EUR 0.20). Occupancy rate rose to 88.9%. The core business "care for elderly and patients" in the segments inpatient and outpatient still shows high vacancies, although total occupancy rate has increased by almost 2% in the last business year. At this point the company still has significant potential which has not been made accessible yet. The general skills shortage in Germany hinders the company from rapidly improving capacity utilization in its facilities. Internal reorganization including decentralization of the operational business is not completed. With the appointment of Dieter Wopen as new member of the management board starting on 15 November 2012 the company shall insofar "gain speed". The contract with chairman Michael Thanheiser was prematurely prolonged until 31 March 2017. The annual report 2011/2012 will be published on Monday, 08 October 2012. end of ad-hoc-announcement ================================================================================ About Marseille-Kliniken AG: Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57 residential care facilities, three residential units for assisted living and about 4,700 employees is a market leading listed company on health care in Germany. The business model is significantly influenced by the demographic development. Therefore Marseille-Kliniken AG has a secured future. Short-term economic fluctuations on the other hand exert only a minor influence. As a consistently modern company with strong focus on quality, the private enterprise is in a good position within a competitive environment primarily characterized by regionally active charities. Further inquiry note: Hillermann Consulting Jan Pahl Investor Relations for Marseille-Kliniken AG Poststraße 14-16 20354 Hamburg Germany Tel.: +49 - (0)40 / 3202791-0 www.marseille-kliniken.de end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: Marseille-Kliniken AG Alte Jakobstraße 79/80 D-10179 Berlin phone: +49 (0)30 246 32-400 FAX: +49 (0)30 246 32-401 mail: info@marseille-kliniken.de WWW: http://www.marseille-kliniken.de sector: Pharmaceuticals ISIN: DE0007783003 indexes: CDAX, Classic All Share, Prime All Share stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing: Hamburg, regulated dealing/prime standard: Frankfurt language: English
Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell